Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum WPD Pharmaceuticals Inc WPDPF


Primary Symbol: C.WBIO

WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in... see more

CSE:WBIO - Post Discussion

WPD Pharmaceuticals Inc > WPD receives approval for Annamycin dose escalation
View:
Post by etcetera on Apr 29, 2020 9:50am

WPD receives approval for Annamycin dose escalation

2020-04-29 07:33 ET - News Release

 

Mr. Mariusz Olejniczak reports

WPD PHARMACEUTICAL'S ANNAMYCIN DRUG APPROVED FOR ACCELERATED EUROPEAN CLINICAL TRIAL

Through its licence partner, Moleculin Biotech Inc., WPD Pharmaceuticals Inc. has been authorized by the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, known as URPL, to accelerate the phase 1 dose escalation portion of its clinical trial of Annamycin for the treatment of acute myeloid leukemia (AML).

https://www.stockwatch.com/News/Item?bid=Z-C%3aWBIO-2897150&symbol=WBIO&region=C

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities